Work

Transcription factors and epigenetics in breast cancer : new findings in CDH3/P-Cadherin gene regulation

Year: 2010
Type: dissertation
Abstract: Breast cancer is the leading cause of cancer amongst women in the westernized world. It is a heterogeneous disease ranging from premalignant hyperproliferation to invasive and metastatic carcinomas. Disease progression is poorly understood but is likely due to the accumulation of genetic alterations leading to widespread changes in gene expression, ultimately affecting cell biology and often increasing growth capacity and survival advantage. Consistent with this, recent studies have shown that different breast tumour subclasses display distinct gene expression profiles. In addition to genetic alterations, there is increasing evidence for gross epigenetic alterations in tumour cells, both at the levels of DNA methylation and histone marks. Epigenetic alterations target and modulate several important genes in breast cancer, contributing, not only for its initiation, but also for its development and response to therapies. One of the key genes in breast biology and cancer, which expression and molecular function is strongly regulated by epigenetic modifications, is the ligand-activated transcription factor oestrogen-receptor α (ERα), the primary mediator of the ovarianproduced steroid hormone oestrogen action in breast mammary cells. Breast cancer development and progression is, in fact, closely associated with the presence or absence of ERα being an important prognostic and predictor indicator in this disease. Consequently, the leading drugs used for endocrine therapy of breast cancer, namely anti-oestrogens such as tamoxifen or fulvestrant, block ERα activity. Despite the efficacy of these target agents during short/medium time regimens, the use of endocrine therapy is limited by the onset of drug resistance, normally mediated by epigenetic alterations, in which most patients, who initially respond favourable to endocrine therapy, eventually recur. In the present thesis we present an immunohistochemical approach involving two ERα- signalling pathways-related transcription factors, FOXA1 and GATA-3, in order to assess whether their expression could be useful as prognostic markers in breast cancer patients. We demonstrated that patients harbouring FOXA1-positive tumours show a better diseasefree survival in a 5 years follow-up time and that FOXA1 expression associates with good prognosis clinicopathological features. More importantly, and for the first time, we established that this forkhead-box transcription factor has a power for recurrence risk stratification among the poor prognostic ERα-negative breast cancer patients, demonstrating the clinical importance of this biomarker in breast cancer prognosis. We still demonstrated that GATA-3 does not constitute a strong predictor for breast cancer diseasefree survival nor a good prognostic marker, but was shown to be a robust luminal differentiation marker. Taken together, the expression assessment of FOXA1 and GATA-3 can provide important clinical information, not only regarding the favourable prognostic outcome, but can also constitute an important tool to define and assess the luminal A subtype in breast cancer and, eventually, response to endocrine therapy. ERα-negative breast cancers are resistant to endocrine therapies and have a worse prognosis than ERα-positive breast cancers. DNA methylation and chromatin remodelling are two epigenetic mechanisms that have been linked with a generation of an aggressive ERα-negative phenotype in breast cancer. Endocrine therapies have been reported to interfere with the expression of ERα-repressed genes, ultimately leading to the ERα- negative phenotype of breast cancer, but most importantly, with the induction of breast cancer cell aggressiveness and invasiveness in specific cell contexts. We have been focussed on studying CDH3/P-cadherin gene expression, as an ERα-repressed gene in breast cancer; enlightening a mechanism for its regulation in a breast cancer cell model. The mechanism by which ERα-signalling inhibition led to P-cadherin overexpression was completely unknown until now. Herein, we described a chromatin remodelling (H3K4me2) at CDH3 gene regulatory region which, being induced by ICI 182,780 treatment, can modulate CDH3 promoter activity and the expression of a pro-invasive protein in breast cancer, as Pcadherin. Moreover, this study allowed the identification of a new transcription factor, C/EBPα that is able to regulate CDH3 activity in breast cancer cell lines and which expression associates with P-cadherin in breast cancer patient samples. Overall, the work summarized in this thesis discusses molecular characteristics that may influence the risk for ERα-negative breast cancer patients to recur, also suggesting two new markers which, in addition to ERα assessment, might be useful for predict breast cancer outcome in patients non-responsive to endocrine therapies. Moreover, we demonstrated a chromatin remodelling event provoked by the pure anti-oestrogen ICI 182,780, which is able to increase CDH3 promoter activity and therefore, the expression of the pro-invasive protein P-cadherin in breast cancer cells, contributing to the elucidation of how breast cancer cells may acquire aggressive properties after loss of oestrogen signalling.
Institution: University of Minho
Language: English
Subfield: Endocrinology
Open Access status: green
OpenAlex ID: W37980828
Cites: 248
Cited by:
Related to: 8